Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
for
Ovarian Cancer, Fallopian Tube Cancer
Location: Boston MA, New York NY, Philadelphia PA, Durham NC,
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 18+
Code: NCT05287451
Recruiting
Active & Responsive
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
for
Premalignant Lesion
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06561087
Phase 2, Recruiting
Active & Responsive
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06066424
Phase 1, Recruiting
Active & Responsive
What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
for
Breast Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 30+
Code: NCT04794816
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
for
Hodgkin Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 2 - 21
Code: NCT07551583
Phase 2, Recruiting
Active & Responsive
Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
for
Cutaneous Angiosarcoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07655570
Phase 2, Recruiting
Active & Responsive
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
for
Colorectal Cancer, Regorafenib, High Risk Patients
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07071961
Phase 2, Recruiting
Active & Responsive
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
for
Melanoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06683755
Phase 1, Phase 2, Recruiting
Active & Responsive
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
for
Non-small Cell Lung Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07382726
Phase 1, Recruiting
Active & Responsive
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
for
Phase 1b, Open Label, REC-617, RB1-Negative, Leiomyosarcoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07633756
Phase 1, Recruiting
Active & Responsive
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
for
Chronic Myeloid Leukemia
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06817720
Phase 2, Recruiting
Active & Responsive
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)
for
Communication Skills, Professionalism,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07089953
Recruiting
Active & Responsive
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
for
T-cell Prolymphocytic Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07311746
Phase 1, Phase 2, Recruiting
Active & Responsive
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
for
Recurrent B-Cell Non-Hodgkin Lymphoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07283679
Phase 1, Phase 2, Recruiting
New
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
for
Sarcoma,Soft Tissue
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18 - 39
Code: NCT07874828
Phase 2, Recruiting
New
Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas
for
High Grade Gliomas
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 3 - 21
Code: NCT07649070
Phase 2, Recruiting
New
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
for
Ann Arbor Stage III Grade 1 Follicular Lymphoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT04404088
Phase 2, Recruiting
New
Spatial Computing With the Apple Vision Pro in Image-guided Procedures
for
Apple Vision Pro, Image Guided Procedure, Spatial Computing
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07819513
Recruiting
New
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum